PpProf. Peptide
← Back to Comparisons

Semax vs Selank — Cognitive Peptide Comparison

Semax and Selank are both synthetic nootropic peptides developed in Russia, both approved for clinical use there, and both studied for cognitive and anxiolytic effects. They work through different mechanisms and have distinct primary strengths — Semax is the cognitive enhancer and neuroprotector, Selank is the anxiolytic with cognitive benefits.

Why Russian peptide research diverged from Western

Both Semax and Selank were developed in Soviet/Russian neuroscience institutes starting in the 1980s. Russian peptide research took a different path from Western pharmacology, focusing heavily on small synthetic peptides modeled on natural neuropeptides — a class largely overlooked in Western drug development.

Semax is derived from ACTH (adrenocorticotropic hormone, the body's stress response peptide). Specifically, it's a fragment of ACTH (positions 4-7) modified to remove ACTH's hormone-stimulating effects while preserving its cognitive and neuroprotective properties. The result: a peptide that boosts BDNF (brain-derived neurotrophic factor — protects and grows neurons) and supports cognition without affecting cortisol.

Selank is derived from tuftsin, an immunoregulatory peptide naturally produced from immunoglobulins. The modification gave Selank anxiolytic (anxiety-reducing) properties without the sedation, dependence, or memory effects associated with benzodiazepines. It works through a different mechanism than benzos — modulating GABA-A receptors allosterically rather than activating them directly.

Both are FDA-unapproved in the US but ARE approved by Russia's regulatory body for clinical use. Both administer intranasally (sprays). Both have peer-reviewed Russian research and growing English-language interest. The key differences come down to primary effect: Semax for cognition and neuroprotection, Selank for anxiety reduction.

SemaxSelank
OriginACTH (adrenocorticotropic hormone — the body's stress hormone) (4-7) analogTuftsin (a naturally occurring immune-modulating peptide that Selank is derived from) analog
Primary MechanismBDNF (brain-derived neurotrophic factor — protects and grows neurons) upregulation, trkB (the BDNF receptor) activation, neuroprotectionGABA-A (the brain's primary inhibitory receptor — calms neural activity) receptor allosteric modulation (changing receptor sensitivity rather than directly activating), BDNF modulation
Primary EffectCognitive enhancement, neuroprotection, stroke recoveryAnxiolytic (anxiety-reducing) — reduces anxiety without sedation or dependence
AnxietyModerate anxiolytic effects secondaryPrimary effect — comparable to benzodiazepines in one RCT without side effects
Cognitive EnhancementPrimary — improves attention, memory, executive functionSecondary — anti-fatigue and mild psychostimulant effects
NeuroprotectionStrongest application — used clinically in Russia for strokePresent — BDNF mediated, protective against alcohol-induced cognitive decline
Clinical Use (Russia)Approved for stroke, encephalopathy, Parkinson’s, ADHDApproved as anxiolytic for generalized anxiety disorder
Dependence RiskNone demonstratedNone — key advantage over benzodiazepines
AdministrationIntranasal sprayIntranasal spray
SedationNoneNone — anxiolytic without sedation
Human Trial DataLimited English-language data — mostly Russian publicationsOne RCT (62 patients, GAD) — comparable to medazepam

Which one is right for you?

Both peptides are research compounds in the US (FDA-unapproved) but clinically used in Russia. Application choice depends primarily on what you're researching: cognition or anxiety.

Cognitive enhancement, focus, mental performance

Semax is the more direct match. Russian clinical research approves it for stroke recovery, encephalopathy, ADHD, and cognitive impairment — all centered on its BDNF-elevating, neuroprotective mechanism. Self-reported effects in research-using populations include improved focus, mental clarity, and faster learning. Onset is fairly quick (within hours of intranasal dosing).

Anxiety reduction without sedation or dependence

Selank is the more direct match. Russia approves it for generalized anxiety disorder (GAD). The standout feature: in one RCT (62 patients with GAD), Selank was comparable to medazepam — a benzodiazepine — in anxiety reduction, but without sedation, memory impairment, or dependence risk. For research interested in anxiolysis without benzodiazepine downsides, this is an unusual peptide.

Stress recovery, neuroprotection, brain injury research

Both have neuroprotective evidence, but Semax has stronger data for acute neuroprotection (stroke, traumatic brain injury, cognitive decline). Russian clinics use Semax post-stroke. Selank's neuroprotection is more about chronic stress resistance — protective against alcohol-induced cognitive decline in animal models.

Stack approach (cognitive + anxiety together)

Some research protocols use both. Mechanisms don't overlap (BDNF/trkB for Semax, GABA-A allosteric modulation for Selank), so combined effects are theoretically additive. The combination is sometimes positioned as “Semax for productivity, Selank for stress.” No formal research has compared the stack to single-peptide protocols.

Bottom Line

Choose Semax if the primary research interest is cognitive enhancement, neuroprotection, or stroke-related outcomes. Choose Selank if the primary interest is anxiety reduction without sedation or dependence risk. They complement each other well — Semax for cognition, Selank for stress — and are sometimes studied together.

FAQ

How are these legal in Russia but not the US?

Russia's regulatory framework approved both peptides through their pharmacological standards based on Russian-conducted clinical trials. The FDA requires its own trials for US approval, which neither peptide has undergone. This is a common pattern with Russian peptides — they're sold legally in Russia as approved medications, but in the US they're sold only as research compounds. No legal pathway currently exists to import either for human use in the US.

How are they administered?

Both are intranasal sprays. The intranasal route is critical — it allows the peptides to cross the blood-brain barrier directly via nasal-to-CNS pathways, avoiding the digestive degradation that would happen with oral dosing. Effects begin within 15–60 minutes. Standard research dosing is 1–3 sprays per nostril per session, dosed 2–4 times daily.

Are there side effects?

Both have unusually clean side effect profiles in research. Semax: rare mild irritation at the application site, occasional headache. Selank: rare drowsiness or mild dizziness, no dependence or withdrawal even after extended use. Neither causes the cognitive blunting, dependence, or rebound symptoms associated with conventional anxiolytics.

Can I take Semax and Selank together?

Yes, no documented interactions. Mechanisms are different (BDNF vs GABA-A) so combined effects are likely additive. Some research protocols dose Semax in the morning (cognitive enhancement) and Selank in the evening or as needed (anxiety reduction).

How does Selank compare to benzodiazepines?

One RCT (62 patients with GAD, Russian, 2008) compared Selank to medazepam: comparable anxiety reduction, but Selank produced no sedation, no memory impairment, no dependence, and no rebound anxiety on discontinuation. This trial is small and not independently replicated outside Russia. The mechanism (allosteric GABA-A modulation) is biologically plausible for explaining the cleaner effect profile.

Will these show up on drug tests?

Neither is on standard drug screening panels (5-panel, 10-panel, expanded employment panels). They're not tested for in WADA athletic screening either, though policy may evolve as awareness grows. Custom mass-spectrometry testing could detect them, but no commercial tests target these peptides.

For educational and research purposes only. Not medical advice. Not for human use.

Have a question about Semax vs Selank — Cognitive Peptide Comparison? Send us an email →